



**SANIFIT**

**Laboratoris Sanifit S.L.**

PARC BIT | Europa Building 2nd Floor | 07121 Palma (Spain)

Tel: +34 971 439 425

[info@sanifit.com](mailto:info@sanifit.com) | [www.sanifit.com](http://www.sanifit.com)

**Sanifit is delighted to Announce that Dr Joan Perelló has been granted the “CEO Today Europe Award”**

The international magazine CEO Today has published a list with the 100 Europe’s most talented Chief Executive Officers whose commitment to excellence and achievements are worth cheering for.

Every year CEO Today Magazine identifies and honors the most progressive, forward-thinking and ambitious company leaders in todays’ business. The CEO Today team collate votes and in-depth sector by sector research to choose the very best of the best among the Europe’s CEOs. The Magazine also identifies top talented CEOs in USA, Africa and Middle East.

The winners are a group of inspiring individuals from different professional sectors, dedicated to achieving success, whilst making a lasting impact. Including Dr. Perelló, only 3 CEOs from life science branch have been awarded.

Sanifit is pleased to congratulate its CEO, Dr. Joan Perelló Bestard for this well-deserved award. Congratulations, Joan!!!

*To view all the winners profile and the awards publication, please visit:*

<https://europeawards.ceotodaysmagazine.com/winners-edition/>





**For media enquiries:**

**Sanifit**

Joan Perelló, CEO

Antonio Jiménez, VP Operations

**About Sanifit**

Sanifit is a biopharmaceutical company focused on the development of SNF472. The company was founded in 2007 as a spin-off of the University of the Balearic Islands and expanded its activities in the USA in 2016 with the incorporation of a subsidiary with offices in San Diego. SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease (ESRD) population undergoing haemodialysis. Sanifit has completed Phase I studies with healthy volunteers and haemodialysis patients and a Phase II study in the orphan space in calciphylaxis, after a series C funding round of \$41.3M (€36.6M) in 2015. Another Phase II program in ESRD is underway. For more information please visit [www.sanifit.com](http://www.sanifit.com)

